This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Headquartered in Hercules, CA, Bio-Rad Laboratories is a manufacturer and global supplier of clinical diagnostics and life science research products in the healthcare, analytical chemistry life science research and other markets. It offers a wide portfolio of products and systems which allow the separation of complex chemical and biological materials and discovery, analysis and purification of their components. Bio-Rad has extensive and direct distribution channels in over 35 countries outside the United States through subsidiaries which focus on sales, customer service and product distribution.
Thermo Fisher (TMO) Gets EUA From FDA for COVID-19 Testing
by Zacks Equity Research
The emergency authorization of this test has made Thermo Fisher (TMO) a key player in the field of coronavirus diagnosis.
Why Is Bio-Rad (BIO) Down 8.3% Since Last Earnings Report?
by Zacks Equity Research
Bio-Rad (BIO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Bio-Rad Launches SARS CoV-2 Standard for Coronavirus Testing
by Zacks Equity Research
With the launch of Bio-Rad's (BIO) SARS CoV-2 Standard, it aims to help laboratories validate coronavirus testing and accelerate the access to testing.
Bio-Rad (BIO) Q4 Earnings & Revenues Fall Short of Estimates
by Zacks Equity Research
Bio-Rad's (BIO) fourth-quarter 2019 results reflect strong segmental performances.
Bio-Rad Laboratories (BIO) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Bio-Rad (BIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Bio-Rad Gains on New Product Portfolio Despite Currency Woes
by Zacks Equity Research
Bio-Rad's (BIO) new product uptake in the United States is appreciative with the recent 510(k) clearance of the IH-Reader 24.
Bio-Rad's Blood Typing Market Growth Strong on New Products
by Zacks Equity Research
Bio-Rad's (BIO) new product acceptance in the United States is a positive with the recent 510(k) clearance of the IH-Reader 24.
Bio-Rad (Bio) Q3 Earnings Beat Estimates on All-Line Growth
by Zacks Equity Research
Growing strength in many of Bio-Rad's (Bio) key product lines across major geographic regions buoys investors' optimism on the stock.
Bio-Rad Laboratories (BIO) Q3 Earnings Beat Estimates
by Zacks Equity Research
Bio-Rad (BIO) delivered earnings and revenue surprises of 18.38% and -0.14%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Bio-Rad Laboratories (BIO) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Bio-Rad (BIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
LabCorp (LH) Names Two Leaders for Major Business Wings
by Zacks Equity Research
Managenment believes that under Schechter's term with Paul and John's crucial support, LabCorp (LH) looks well-positioned to grow and thrive in times ahead.
Bruker To Buy Freiberg Instruments' Magnettech EPR Business
by Zacks Equity Research
The Freiberg Instruments' Magnettech EPR business acquisition is expected to boost Bruker's (BRKR) BioSpin business by complementing its existing range of EPR offerings.
Abbott (ABT) Gets FDA Nod for New Troponin-I Blood Test
by Zacks Equity Research
The regulatory go-ahead for Abbott's (ABT) ARCHITECT STAT High Sensitivity Troponin-I blood test is a major stride forward in its commitment for detecting patients suspected of having a heart attack.
Bio-Rad (BIO) Up 8.8% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Bio-Rad (BIO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Retain Bio-Rad (BIO) Stock for Now
by Zacks Equity Research
Investors' confidence continues to be high on solid prospects of Bio-Rad (BIO).
PRGO vs. BIO: Which Stock Is the Better Value Option?
by Zacks Equity Research
PRGO vs. BIO: Which Stock Is the Better Value Option?
Bio-Rad (Bio) Q2 Earnings Beat Estimates, Margins Expand
by Zacks Equity Research
We are upbeat about Bio-Rad's (BIO) year-over-year revenue growth within the Clinical Diagnostics segment in Q2.
Bio-Rad Laboratories (BIO) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Bio-Rad (BIO) delivered earnings and revenue surprises of 12.95% and 1.66%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Bio-Rad Laboratories (BIO) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Bio-Rad (BIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
IVD Market Sustains Momentum: 3 Stocks in Focus
by Trina Mukherjee
In-vitro Diagnostics has successfully proven itself to be the best diagnostic procedures. So, investors can add stocks from this space to their watchlist.
ABT or BIO: Which Stock Has Better Potential Right Now?
by Zacks Equity Research
Abbott (ABT) scores higher than Bio-Rad (BIO) in terms of valuation and one-year price performance.
Here's Why You Should Invest in CONMED (CNMD) Stock Now
by Zacks Equity Research
CONMED (CNMD) continues to benefit from robust international sales, broad product portfolio and persistent focus on R&D.
Luminex (LMNX) Presents ARIES MRSA Assay to FDA for Clearance
by Zacks Equity Research
Luminex (LMNX) submits the ARIES MRSA assay to the FDA for clearance. The company's ARIES system will get a substantial boost once the FDA clearance is through.
Bio-Rad (BIO) Down 6.9% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Bio-Rad (BIO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Retain Bio-Rad (BIO) Stock For Now
by Zacks Equity Research
Bio-Rad (BIO) continues to witness high investor confidence on strength in the Life Sciences segment.